Global EGFR-TKI Market Growth 2024-2030

Global EGFR-TKI Market Growth 2024-2030

EGFR-TKI (epidermal growth factor receptor tyrosine kinase inhibitors) are a class of targeted therapies designed to treat cancers driven by mutations in the EGFR gene, particularly non-small cell lung cancer (NSCLC).These drugs work by specifically inhibiting the tyrosine kinase activity of the EGFR.

The global EGFR-TKI market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.

LP Information, Inc. (LPI) ' newest research report, the “EGFR-TKI Industry Forecast” looks at past sales and reviews total world EGFR-TKI sales in 2023, providing a comprehensive analysis by region and market sector of projected EGFR-TKI sales for 2024 through 2030. With EGFR-TKI sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world EGFR-TKI industry.

This Insight Report provides a comprehensive analysis of the global EGFR-TKI landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on EGFR-TKI portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global EGFR-TKI market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for EGFR-TKI and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global EGFR-TKI.

United States market for EGFR-TKI is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

China market for EGFR-TKI is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Europe market for EGFR-TKI is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Global key EGFR-TKI players cover AstraZeneca, Roche, Betta Pharma, Boehringer Ingelheim Pharmaceuticals, Pfizer, etc. In terms of revenue, the global two largest companies occupied for a share nearly

% in 2023.

This report presents a comprehensive overview, market shares, and growth opportunities of EGFR-TKI market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:
Gefitinib
Erlotinib
Icotinib
Afatinib
Dacomitinib
Osimertinib
Aumolertinib
Furmonertinib
Lazertinib
Other

Segmentation by Application:
Hospital and Clinic
Retail Pharmacies
Other

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
AstraZeneca
Roche
Betta Pharma
Boehringer Ingelheim Pharmaceuticals
Pfizer
Chengdu Brilliant Pharmaceuticals
Hansoh Pharma
ArriVent Biopharma
Hanmi Pharmaceutical
Johnson & Johnson
Yuhan Corporation
Shanghai Allist Pharmaceuticals
Wanbang Biopharmaceuticals
Beacon Pharma
Drug International
Teva
Mylan
Glenmark Pharmaceuticals
Cipla

Key Questions Addressed in this Report

What is the 10-year outlook for the global EGFR-TKI market?

What factors are driving EGFR-TKI market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do EGFR-TKI market opportunities vary by end market size?

How does EGFR-TKI break out by Type, by Application?



Please note: The report will take approximately 2 business days to prepare and deliver.